---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-25-000048"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2025-06-03T23:59:59+00:00"
generated_at: "2026-05-20T02:03:00.948682+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience acquires two dopamine agonist candidates for TRD and Parkinson's

## Summary
- Alto paid $1.75M cash plus $1.2M expense reimbursement upfront, with up to $71.5M in milestone payments ($41M commercial).
- Acquired CTC-501 (renamed ALTO-207) for treatment-resistant depression and CTC-413 (ALTO-208) for Parkinson's disease.
- Phase 2a of CTC-501 met primary endpoint; patients reached mean 4.1 mg/day, 67% achieved 5 mg, MADRS improvement d=1.1 (p=0.025).
- Alto expects to initiate a potentially pivotal Phase 2b trial for ALTO-207 by mid-2026, with topline data in 2027.
- Cash guidance unchanged; current cash expected to fund operations into 2028 through at least five planned clinical readouts.

## SEC filing metadata
- accession: 0001999480-25-000048
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2025-06-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000048/0001999480-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000048/alto-20250531.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-25-000048
- JSON: https://secwatch.observer/filing/0001999480-25-000048.json
- Plain text: https://secwatch.observer/filing/0001999480-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.